Skip to main content
. Author manuscript; available in PMC: 2019 Apr 22.
Published in final edited form as: J Control Release. 2017 Nov 13;269:364–373. doi: 10.1016/j.jconrel.2017.11.021

Fig. 5.

Fig. 5.

CP-Dox treatment increases the intratumoral ratio of Th1 to Th2 cytokines and requires IFN-γ for full efficacy. Mice were inoculated with 4T1 and treated with drug as described earlier. Tumors were homogenized and analyzed for cytokine levels. (A) Th1 cytokine levels: IFN-γ, left and IL-12 p70, right (n = 4/group) (B) Th2 cytokine levels: IL-4, left (n = 4/group), IL-5, middle (n = 4/group), and IL-6, right (n = 3 CP-Dox, 4 Free Dox, 4 PBS). (C) Normalized and averaged Th1 vs. Th2 cytokine levels by drug treatment (left) and Th1/Th2 ratio (right) (n = 4/group). (D) Primary tumor growth in the setting of IFN-γ depleting antibody on days 7, 9, 15 and 21 (n = 5:5 CP-Dox, 4:4 Free Dox, 4:3 PBS for α-IFN-γ:Iso Ctrl). Data for bar graphs analyzed by ANOVA and Tukey’s post hoc, tumor growth curves analyzed by two-way ANOVA and Tukey’s post hoc. *p < 0.05.